Adult Vaccination – Updates, Developments and New Zoster Jab

Trending3.5(New)

Adult Vaccination – Updates, Developments and New Zoster Jab is a comprehensive Continuing Professional Development (CPD) course designed for healthcare professionals involved in adult immunisation, preventive healthcare, and elderly patient management. The course explores the latest advancements in adult vaccination programmes, emerging vaccine technologies, immunosenescence, and the expanding role of recombinant zoster vaccines such as Shingrix in reducing herpes zoster complications among older adults and immunocompromised populations. The course provides an overview of vaccine-preventable diseases that continue to pose significant health risks in ageing populations, including influenza, pneumococcal disease, respiratory syncytial virus (RSV), COVID-19, and herpes zoster. Learners will examine current immunisation recommendations, updates in national vaccination schedules, and evidence-based strategies to improve vaccine uptake in adults.

7 Modules1 hour
$169$0
Start Learning
Adult Vaccination – Updates, Developments and New Zoster Jab

Learning Outcomes

What you'll learn

  • Identify the vaccine-preventable diseases that currently pose the greatest risk in elderly populations.
  • Define immunosenescence and outline its effects on immune function and vaccine response.
  • Outline the clinical features, complications, and epidemiology of herpes zoster infection.
  • Discuss new developments in vaccine production and immunisation strategies that benefit adults over the age of 65.
  • Apply evidence from the Shingrix clinical trials to patient education and immunisation practice.
  • Explain current recommendations for recombinant zoster vaccination in immunocompetent and immunocompromised adults.
  • Evaluate barriers to adult vaccination uptake and strategies to improve vaccine acceptance.
  • Promote evidence-based adult immunisation practices in primary care and community healthcare settings.

Stay updated with our

Healthcare trainingHealthcare training

Training Overview

  • Adult Vaccination and Ageing Populations
  • Immunosenescence and Age-Related Immune Changes
  • Herpes Zoster Infection and Clinical Features
  • New Zoster Jab – Shingrix and Vaccine Developments
  • Adult Immunisation Schedules and Clinical Practice
  • Future Directions in Adult Vaccination
Healthcare trainingHealthcare trainingHealthcare trainingHealthcare trainingHealthcare trainingHealthcare trainingHealthcare training

Top reviews

No reviews yet.

You May Also Like

Take Your
Learning Anywhere

Stay on top of your learning with the Care Learning app.

Download on the App StoreGet it on Google Play

Are you a qualified
Trainer or Instructor?

Join Care Learning as a trainer and deliver high-quality courses to learners across healthcare and workplace training.

Refer a Friend &
Earn Rewards.

Invite healthcare professionals to join Care Learning and get rewarded when your referral successfully joins.

1 / 3

Frequently asked questions

Immunosenescence refers to the gradual decline in immune system function associated with ageing, resulting in increased infection risk and reduced vaccine responsiveness.

Shingles occurs when latent varicella-zoster virus, which causes chickenpox, reactivates later in life due to reduced immune function.

Shingrix is a recombinant zoster vaccine used to prevent shingles and related complications such as postherpetic neuralgia.

Current recommendations generally include adults aged 50 years and older, as well as immunocompromised adults aged 19 years and older.

Common side effects include injection-site pain, fatigue, fever, headache, and muscle aches, which usually resolve within a few days.

Adult vaccines help prevent severe infections, reduce hospitalisations, improve quality of life, and protect vulnerable populations from preventable diseases.